Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.

Migraine/ The word migraine included in the notes on the wooden background.
The market for preventative therapies has a new option coming this year. • Source: Shutterstock

The launches in 2018 of three closely watched calcitonin gene-related peptide (CGRP) inhibitors as preventive therapies and the anticipated launches of three more products against the same target have brought new attention to migraine decades after the launch of triptans – the last big class of drugs to treat the disease’s debilitating headaches and other symptoms. But while the migraine market is large, the first round of CGRP inhibitors have yet to achieve blockbuster status.

Amgen Inc./Novartis AG’s Aimovig (erenumab) targets the CGRP receptor while Eli Lilly & Co.’s Emgality (galcanezumab) and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Market Snapshot

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 
• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

 
• By Alaric DeArment

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

 
• By Mandy Jackson

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

 
• By Mandy Jackson

Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains